Safety of olanzapine for the prevention of postoperative nausea and vomiting

Safety of olanzapine for the prevention of postoperative nausea and vomiting - Safety of olanzapine

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013908

Enrollment

Registered

2014-05-12

Start date

2014-06-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gynecological begnin diseases

Interventions

olanzapine

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Patients 1) who receive laparoscopic gynecological surgery for benign disease. 2) who are equal to or older than 20 years old. 3) with American Society of Anesthesiologists Physical Status 1 or 2

Exclusion criteria

Exclusion criteria: Patients 1) who receive epidural anesthesia 2) who were contraindicated to any of the study drugs 3) who have diabetes 4) who take emetogenic or antiemetic drugs within the 24 hours before surgery, 5) who receive emergency surgery 6) who receive open surgery 7) who are pregnant or lactating

Design outcomes

Primary

Measure	Time frame
extrapyramidal syndrom, excessive sedation, hyperglycemia, arrythmia	—

Countries

Japan

Contacts

Public ContactHiroyuki Seki

School of Medicine, Keio University Department of Anesthesiology

hshiroyukiseki@gmail.com03-3353-1211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026